Neuromity is pioneering treatments for neurological disorders using deuterium-enabled chiral switching (DECS). Our lead program, NTY-184 (deuterium-stabilized S-bupropion), is being developed initially for major depressive disorder (MDD) as an NCE with new composition of matter IP via an expedited and derisked 505(b)(2) regulatory pathway.
Company Details
- Founded
- 2021
- Address
- 800 Boylston St, Boston,massachusetts 02116,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.neuromity.com
- Keywords
- Reno.
- HQ
- Boston, Massachusetts
Neuromity Therapeutics, Inc. Questions
Neuromity Therapeutics, Inc.'s website is http://www.neuromity.com
Neuromity Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/neuromity
Neuromity Therapeutics, Inc.'s industry is
Pharmaceutical Manufacturing
Neuromity Therapeutics, Inc.'s top competitors are
Deuterx,
Hopewell Therapeutics, Inc.,
Enveric Biosciences, Inc.,
Myris Therapeutics,
Deuteria Beverages, Llc,
Salarius Pharmaceuticals,
Protia, Llc,
Metis Therapeutics,
Minerva Biotechnologies,
Arsenica Llc.
Neuromity Therapeutics, Inc.'s categories are Pharmaceutical Manufacturing
Neuromity Therapeutics, Inc.'s founding year is 2021
